01—Abstract
Summary
Summary of the 10-K filed May 8, 2000. Cited figures are marked; the original filing is the authoritative source.
Charles River Laboratories Holdings, Inc. reported fiscal 1999 total net sales of $219.3 milliona ($219,276 thousand), up from $193.3 million in 1998 and $170.7 million in 1997.
Growth came from both segments: net sales related to services rose to $39.0 millionb from $23.9 million, and net sales related to products rose to $180.3 million from $169.4 million. Operating income increased to $43.0 million from $35.3 million, but net income fell to $17.1 million from $23.4 million, or $1.66 per share versus $2.27. The decline reflected interest expense of $12.8 million, compared with $0.4 million in 1998, following the recapitalization.
On September 29, 1999, CRL Acquisition LLC, an affiliate of DLJ Merchant Banking Partners II, L.P. and affiliated funds, acquired 87.5% of the common stock of Charles River Laboratories, Inc. from Bausch & Lomb for approximately $443 millionc, in a leveraged recapitalization accounted for without changing the historical basis of assets and liabilities. Bausch & Lomb subsidiaries retained 12.5%. The transaction left the company with total liabilities of $459.7 million, long-term debt of $381.7 million, and a shareholders' deficit of $(110.1) million at year-end.
The filing states the holding company has no source of liquidity of its own, so repayment depends on dividends from the operating subsidiary, which are restricted by debt terms, or on a refinancing or equity transaction. Operating cash flow was $37.6 milliond in 1999, roughly flat with $37.4 million in 1998, and capital expenditures were $13.0 million.
The company spent $23.1 million on acquisitions, including Sierra, a preclinical biomedical services company acquired for about $23.3 million. Subsequent events include the acquisition of an additional 16% of the Charles River Japan joint venture for 1.4 billion yen ($12,844 thousand), which will bring its operations into consolidation, and the planned closure of the Shamrock primate import business in England.
02—Key points
Key Highlights
- Total net sales rose to $219.3 million in 1999 from $193.3 million in 1998, with services sales increasing to $39.0 million from $23.9 million.
- Operating income increased to $43.0 million from $35.3 million, while net income declined to $17.1 million from $23.4 million, or $1.66 per share from $2.27.
- Interest expense rose to $12.8 million from $0.4 million, reflecting the debt used in the September 29, 1999 recapitalization.
- DLJMB funds acquired 87.5% of Charles River Laboratories, Inc. from Bausch & Lomb for approximately $443 million; Bausch & Lomb subsidiaries retained 12.5%.
- At year-end the company had long-term debt of $381.7 million, total liabilities of $459.7 million, and a total shareholders' deficit of $(110.1) million.
- Operating cash flow was $37.6 million, capital expenditures were $13.0 million, and acquisitions used $23.1 million, including Sierra for about $23.3 million.
- Subsequent events include the purchase of an additional 16% of Charles River Japan for 1.4 billion yen ($12,844 thousand) and the planned closure of the Shamrock primate business in England.
03—Questions
Frequently Asked Questions
Why did net income fall in 1999 even though operating income grew?
Operating income rose to $42,963 thousand from $35,325 thousand, but interest expense increased to $12,789 thousand from $421 thousand after the recapitalization financing. The filing also reports a 1999 effective tax rate of 50.7%, compared with 39.5% in 1998. Net income therefore decreased to $17,124 thousand from $23,378 thousand.
What was the recapitalization and how was it financed?
On September 29, 1999, CRL Acquisition LLC, an affiliate of DLJ Merchant Banking Partners II and affiliated funds, acquired 87.5% of Charles River Laboratories, Inc. from Bausch & Lomb for about $443 million. The transaction was funded by 150,000 units of 13.5% senior subordinated notes with warrants ($150.0 million), $162.0 million of senior secured credit facility borrowings, $37.6 million of senior discount debentures with warrants, a $43.0 million subordinated discount note to Bausch & Lomb, and $92.4 million of equity from the investors.
Can the holding company repay its debt on its own?
No. The filing states that Charles River Laboratories Holdings, Inc. is a holding company with no operations or operational assets other than its ownership of Charles River Laboratories, Inc., and no source of liquidity to meet its cash requirements. Repayment depends on dividends from the operating subsidiary, which are restricted by the senior subordinated notes indenture and the senior secured credit facility, or on a refinancing or equity transaction.
What major events occurred after year-end 1999?
As of February 28, 2000, the company acquired an additional 16% of Charles River Japan, a 50% equity joint venture, for 1.4 billion yen ($12,844 thousand), and will consolidate its operations from that date. On March 10, 2000, it announced the closure of its Shamrock primate import and conditioning business in Small Dole, England, expected to be completed in the second quarter of 2000. In January 2000, it also sold a research model product line for $7,000 thousand.
04—Continue